Literature DB >> 1918264

Antineutrophil cytoplasmic antibody--a useful serological marker for vasculitis.

J A Goeken1.   

Abstract

Systemic necrotizing vasculitides, including polyarteritis nodosa, Churg-Strauss syndrome, "overlap" systemic vasculitis, Wegener's granulomatosis, and idiopathic crescentic glomerulonephritis, are frequent clinical diagnostic problems. These diseases have diverse presentations and are often rapidly progressive, causing irreversible injury to the vessels of the kidneys and lungs before effective immunosuppressive therapy is instituted. Even in their less fulminant forms, they are a cause of significant morbidity and mortality. Antineutrophil cytoplasmic antibody, a recently identified autoantibody, has a high sensitivity and specificity for this spectrum of diseases. The clinical and pathological similarities, the high frequency of antineutrophil cytoplasmic antibody expression, and the similar good response to immunosuppressive therapy suggest that these diseases may be linked by a common pathophysiological mechanisms. Evidence is growing that antineutrophil cytoplasmic antibody plays a central role in this mechanisms. A revision in the classification scheme of vasculitides to recognize that the polyarteritis group (polyarteritis nodosa, Churg-Strauss syndrome, and "overlap" systemic vasculitis), Wegener's granulomatosis, and idiopathic crescentic glomerulonephritis are closely related diseases may be warranted. The clinical and pathological features of systemic necrotizing vasculitides and the current knowledge concerning antineutrophil cytoplasmic antibodies are reviewed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918264     DOI: 10.1007/bf00917422

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  66 in total

1.  The kidney in periarteritis nodosa.

Authors:  J DAVSON; J BALL; R PLATT
Journal:  Q J Med       Date:  1948-07

2.  A Clinical and Pathological Study of Periarteritis Nodosa: A Report of Five Cases, One Histologically Healed.

Authors:  A Arkin
Journal:  Am J Pathol       Date:  1930-07       Impact factor: 4.307

3.  Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3.

Authors:  J C Jennette; J R Hoidal; R J Falk
Journal:  Blood       Date:  1990-06-01       Impact factor: 22.113

4.  The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision?

Authors:  R A DeRemee
Journal:  Arthritis Rheum       Date:  1988-08

5.  Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis.

Authors:  G Lüdemann; W L Gross
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

6.  Anti-neutrophil cytoplasm antibodies 1988.

Authors:  N Rasmussen; A Wiik; M Høier-Madsen; N Borregaard; F van der Woude
Journal:  Lancet       Date:  1988-03-26       Impact factor: 79.321

7.  Immunopathological studies of polyarteritis nodosa and Wegener's granulomatosis: a report of 43 patients with 51 renal biopsies.

Authors:  P Ronco; P Verroust; F Mignon; O Kourilsky; P Vanhille; A Meyrier; J P Mery; L Morel-Maroger
Journal:  Q J Med       Date:  1983

8.  Association of autoantibodies to myeloperoxidase with different forms of vasculitis.

Authors:  J W Tervaert; R Goldschmeding; J D Elema; P C Limburg; M van der Giessen; M G Huitema; M I Koolen; R J Hené; T H The; G K van der Hem
Journal:  Arthritis Rheum       Date:  1990-08

9.  Pulmonary-renal syndrome: clinical similarity amidst etiologic diversity.

Authors:  S M Bonsib; W P Walker
Journal:  Mod Pathol       Date:  1989-03       Impact factor: 7.842

10.  Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils.

Authors:  R Goldschmeding; C E van der Schoot; D ten Bokkel Huinink; C E Hack; M E van den Ende; C G Kallenberg; A E von dem Borne
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

View more
  10 in total

1.  Pulmonary Wegener's granulomatosis misdiagnosed as malignancy.

Authors:  S Uppal; N Saravanappa; J P Davis; C K Farmer; D J Goldsmith
Journal:  BMJ       Date:  2001-01-13

Review 2.  Small vessel vasculitis of the lung.

Authors:  M I Schwarz; K K Brown
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

3.  Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features.

Authors:  K Nishiya; H Chikazawa; S Nishimura; N Hisakawa; K Hashimoto
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

Review 4.  Primary and secondary vasculitic neuropathy.

Authors:  Gérard Said; Catherine Lacroix
Journal:  J Neurol       Date:  2005-04-05       Impact factor: 4.849

5.  Painful bilateral abducens nerve palsy associated with anti-neutrophil cytoplasmic autoantibodies.

Authors:  N Sanjo; T Yokota; Y Saitou; H Miake; H Tanaka
Journal:  J Neurol       Date:  1996-08       Impact factor: 4.849

Review 6.  Peripheral neuropathy in polyarteritis nodosa.

Authors:  G Said
Journal:  Springer Semin Immunopathol       Date:  1996

Review 7.  Epigenetics and Vasculitis: a Comprehensive Review.

Authors:  Paul Renauer; Patrick Coit; Amr H Sawalha
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

8.  T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis.

Authors:  R Giscombe; J Grunewald; S Nityanand; A K Lefvert
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

9.  A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies.

Authors:  J A Savige; B Paspaliaris; R Silvestrini; D Davies; T Nikoloutsopoulos; A Sturgess; J Neil; W Pollock; K Dunster; M Hendle
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

10.  Pediatric inflammatory bowel disease with cytoplasmic staining of antineutrophil cytoplasmic antibodies.

Authors:  Omar I Saadah; Jamil A Al-Mughales
Journal:  Clin Dev Immunol       Date:  2013-02-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.